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Background: Pregnancy is associated with an increased risk of developing a malaria infection and a higher risk of
developing severe malaria. The pharmacokinetic properties of many anti-malarials are also altered during
pregnancy, often resulting in a decreased drug exposure. Piperaquine is a promising anti-malarial partner drug used
in a fixed-dose combination with dihydroartemisinin. The aim of this study was to investigate the population
pharmacokinetics of piperaquine in pregnant and non-pregnant Sudanese women with uncomplicated Plasmodium
falciparum malaria.
Method: Symptomatic patients received a standard dose regimen of the fixed dose oral
piperaquine-dihydroartemisinin combination treatment. Densely sampled plasma aliquots were collected and
analysed using a previously described LC-MS/MS method. Data from 12 pregnant and 12 non-pregnant women
were analysed using nonlinear mixed-effects modelling. A Monte Carlo Mapped Power (MCMP) analysis was
conducted based on a previously published study to evaluate the power of detecting covariates in this relatively
small study.
Results: A three-compartment disposition model with a transit-absorption model described the observed data well.
Body weight was added as an allometric function on all clearance and volume parameters. A statistically significant
decrease in estimated terminal piperaquine half-life in pregnant compared with non-pregnant women was found,
but there were no differences in post-hoc estimates of total piperaquine exposure. The MCMP analysis indicated a
minimum of 13 pregnant and 13 non-pregnant women were required to identify pregnancy as a covariate on
relevant pharmacokinetic parameters (80% power and p=0.05). Pregnancy was, therefore, evaluated as a categorical
and continuous covariate (i.e. estimate gestational age) in a full covariate approach. Using this approach pregnancy
was not associated with any major change in piperaquine elimination clearance. However, a trend of increasing
elimination clearance with increasing gestational age could be seen.
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Conclusions: The population pharmacokinetic properties of piperaquine were well described by a
three-compartment disposition model in pregnant and non-pregnant women with uncomplicated malaria. The
modelling approach showed no major difference in piperaquine exposure between the two groups and data
presented here do not warrant a dose adjustment in pregnancy in this vulnerable population.
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Malaria is one of the most important infectious diseases
with an estimated 216 million people infected worldwide
in 2010 [1]. Pregnant women are at an increased risk of
developing a malaria infection [2] and are at a higher
risk of progressing to severe malaria [3-5]. Plasmodium
falciparum malaria is a major contributor to maternal
mortality in Sudan; around 37% of all maternal deaths
between 1985 and 1999 at the Medani Teaching Hos-
pital in Medani City, Sudan, were attributed to malaria
[6]. Malaria also has severe effects on the foetus causing
both foetal loss and low birth weight.
Artemisinin-based combination therapy (ACT) is
recommended as first-line treatment for P. falciparum
malaria in all endemic areas. The artemisinin derivatives
have a very rapid parasiticidal effect, which substantially
reduces the parasite biomass during the first days of
treatment. These drugs have a short terminal elimination
half-life and are, therefore, used in combination with
longer acting anti-malarials, with the aim of preventing
recrudescence by killing residual parasites. Combination
therapies consisting of drugs with different mechanisms
of action also reduce the risk of the development of drug
resistance [7,8].
The oral fixed-dose combination of dihydroartemisinin
and piperaquine has shown excellent efficacy in the treat-
ment of P. falciparum malaria [9-13]. Piperaquine is highly
bound to plasma proteins (>99.9%), has a large apparent
volume of distribution, (103–874 L/kg), a low apparent
elimination clearance (0.6-1.3 L/h/kg) and, therefore, a
long terminal elimination half-life (12–28 days) [14-20].
Pregnancy has considerable effects on the pharmaco-
kinetic properties of many drugs. Renal elimination,
expression of metabolising enzymes, volume of body
water and the degree of plasma protein binding all
change during pregnancy [21-23]. This could result in
lower drug plasma concentrations [24]. Previously pub-
lished studies have reported a decrease in drug exposure
during the later stages of pregnancy for artesunate, arte-
mether, dihydroartemisinin, lumefantrine, sulphadoxine,
atovaquone, proguanil and cycloguanil [19,25-31]. Other
anti-malarial drugs (e.g. quinine and amodiaquine/
desethylamodiaquine) show no differences in pharmaco-
kinetic properties in pregnant women compared to non-
pregnant women [32-34].Only one previous study has investigated the impact
of pregnancy on the pharmacokinetic properties of
piperaquine in patients with uncomplicated P. falciparum
malaria [19]. Pregnancy was found to affect the elimin-
ation clearance and the bioavailability of piperaquine, but
with no change in total drug exposure. This was further
supported by a non-compartmental analysis of the same
study [35]. No published information is available on the
population pharmacokinetic properties of piperaquine in
pregnant or non-pregnant women in an African country.
The aim of this study was to describe the population
pharmacokinetic properties of piperaquine in pregnant and




The study was conducted at the New Halfa Teaching
Hospital in New Halfa, Sudan. Clinical details and non-
compartmental analysis results are reported in full else-
where [36]. The participating women received a written
and oral explanation of the study in their own language.
If the woman could not read, the explanation was read
to her. Ethics approval for the study was given by the
College of Medical and Technical Studies, Khartoum,
Sudan.
Symptomatic pregnant women with uncomplicated
P. falciparum malaria in their second or third trimester
attending the antenatal clinic in New Halfa were eligible
to participate in the study. Non-pregnant women with
uncomplicated P. falciparum malaria were also recruited
as controls.
Drug regimen
All patients received dihydroartemisinin-piperaquine
tetra-phosphate (Duo Cotecxin, 40 mg/320 mg tablets,
Beijing Holley-Cotec Pharmaceuticals, Co., Ltd.) once
daily for three days. Drug administration was directly
observed and taken with a glass of water under fasting
conditions. The number of tablets was based on the
patient’s body weight to achieve a daily dose of 20 mg
piperaquine tetra-phosphate/kg.
Blood samples were obtained by venous puncture or a
three-way tap. PCR, haematology and biochemistry sam-
ples were drawn before the first dose and on day 14.
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drawn pre-dose and at 1.5, 4, 8, 24, 25.5, 28, 32, 48, 49,
50, 52, 56, 60, 72 h after the first dose and on days 5, 7,
14, 21, 28, 35, 42, 49, 56, 63 and 90. The actual time
of dosing and sampling were noted and used in the
pharmacokinetic analysis. Blood samples were centri-
fuged at 2000×g for 10 minutes and plasma samples
stored in liquid nitrogen until the samples were trans-
ferred to Khartoum there they were stored in −80°C.
Drug analysis
The chemical analysis was performed using a previously
published method with separation and quantification by
liquid chromatography (LC) and tandem mass spectrom-
etry (MS/MS) detection [37]. The LC-system was an
Agilent 1200 system consisting of a binary LC pump, a
vacuum degasser, autosampler and a column compart-
ment. The MS-system was an API 5000 triple/quadruple
mass spectrometer with a Turbo V ionization source.
The lower limit of quantification (LLOQ) was set to 1.5
ng/mL and the lower limit of detection (LLOD) was set
to 0.38 ng/mL. This method reported an intra- and
inter-day precision of below 10% for all quality control
samples.
Pharmacokinetic and statistical analysis
The data were analysed using nonlinear mixed-effects
modelling as implemented in NONMEM version VI
(Icon Development Solutions, Ellicott City, Maryland,
USA) [38]. Piperaquine plasma concentrations were
transformed into their natural logarithms to increase the
stability of the numeric analysis. Models were fitted to
the data using the first-order conditional estimation
(FOCE) method with interaction [39-41]. Census, ver-
sion 1.1 [42], and Xpose, version 4.04 [43], library for R
was used for model diagnostics. Perl-speaks-NONMEM
(PsN), version 3.4.2, [44] was used to automate the mod-
elling process and for model diagnostics.
Model discrimination was based the on the objective
function value (OFV) computed by NONMEM
as −2×log likelihood [45]. The OFV is approximately χ2
distributed and a decrease in OFV of 3.84 and 6.64 is
considered a significant drop with p<0.05 and p<0.01,
respectively, when adding one additional parameter (one
degree of freedom between two nested models).
Structural models with one-, two-, three- and four-
disposition compartments were fitted to the data. Several
alternative absorption models were investigated; first-
order absorption, first-order absorption with lag time,
zero-order absorption, sequential zero- and first-order
absorption, sequential zero- and first-order absorption
with lag time, parallel first- and zero-order absorption,
parallel first-order absorption and transit compartment
absorption with a fixed number of 1–10 transitcompartments. The full implementation of the transit
compartment absorption model, which allows the num-
ber of transit compartments to vary between patients,
was also evaluated [46].
It was assumed that drug elimination took place from
the central compartment and the base model was para-
meterized as elimination clearance, central volume of
distribution, inter-compartmental clearance(s) and per-
ipheral distribution volume(s). Bioavailability was added
to the model and the population value was fixed to 100%.
The distribution of the individual parameters was
assumed to be log-normal and between-subject variability
(BSV) was investigated on all parameters as an exponen-
tial random effect [Equation 1].
Pi ¼ θp⋅eηi;P ð1Þ
where Pi is the individual estimate for a model par-
ameter (e.g. individual drug clearance) in the ith indi-
vidual. θp is the population mean of parameter P and
ηi,P is individual i
th deviation from the population
mean. BSV is estimated from a normal distribution
with variance ω2 and zero mean. Between dose occa-
sion variability (BOV) was evaluated on absorption
parameters [Equation 2].
Pij ¼ θP⋅e ηi;Pþκj;Pð Þ ð2Þ
Where Pij is the individual parameter estimate for the
ith patient on the jth dose occasion, κ is the deviation
from the population mean after each dose occasion,
taken from a normal distribution with variance Π2 and
zero mean. An additive residual error model was
assumed since data were transformed into their natural
logarithms (i.e. essentially equivalent to an exponential
error model on an arithmetic scale). Body weight was
tried in the model as a simultaneous incorporation of an
allometric function on all clearance (power of 0.75) and
volume parameters (power of 1), considering the strong
biological prior of this covariate relationship [47-49].
Basic goodness-of-fit plots and simulation-based diag-
nostics were used to evaluate the final model. Visual and
numerical predictive checks [50] were performed using
2000 simulations at each concentration-time point with
binning based on protocol times. The 5th, 50th and 95th
percentile of observed data were plotted over the simu-
lated 95% confidence interval of the same percentiles to
evaluate the models predictive performance. Bootstrap
diagnostics were performed using 1000 re-sampled data-
sets, stratified on pregnancy.
A Monte Carlo Mapped Power analysis (MCMP) [51]
was conducted based on results from a previously pub-
lished population analysis [19]. The current study design
in terms of sampling times and doses were used to cre-
ate a modelled data set with 408 pregnant and 408 non-
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lation pharmacokinetic model was used to estimate the
minimum number of individuals needed in each group
(i.e. pregnant and non-pregnant) to identify the
described covariate relationships (i.e. a 45.0% increase in
elimination clearance or a 46.8% increase in bioavailabil-
ity) at a given power (80%) and significance level
(p=0.05). Full power curves were produced by plotting
number of patients needed against the power to detect
the assumed covariate relationship.
Pregnancy was investigated in the final pharmacoki-
netic model utilizing a full covariate approach where
pregnancy was included as a categorical covariate on
all pharmacokinetic parameters. Estimated gestational
age (EGA) was evaluated as a continuous covariate on
individual parameters using a linear and a power
function, and the most appropriate covariate relation-
ship (lowest OFV) was incorporated into a full covari-
ate model for EGA. These two full covariate models
were bootstrapped (n=200) to investigate the impact
of pregnancy. A pregnancy related change in the par-
ameter estimate of more than 20% was deemed to
have clinical relevance.
Results
Fourteen non-pregnant and twelve pregnant women
were recruited into the study but two non-pregnant
women withdrew their consent and were excluded from
the analysis. Full demographics are given in Table 1. The
treatment was well-tolerated, none of the patients vom-
ited after treatment and no severe adverse events were
reported during the study. One non-pregnant woman
had a PCR-confirmed new infection on day 35. None ofTable 1 Admission demographic data of study population
Non-pregna
Median (Ra
Number of patients 12
Daily piperaquine (phosphate) dose (mg/kg) 18.1 (15.1-24
Daily piperaquine (base) dose (mg/kg) 10.5 (8.71-13
Age (years) 21.0 (16.0-43
Body weight (kg) 53.0 (44.0-81
Height (cm) 163 (150–17
Estimated gestational age (weeks) -
Parasitemia (parasites/μL) 13200 (936–
Days of fever 2.5 (1–6)
Fever (°C) 38.3 (36.7-40
Haemoglobin (g/dL) 8.70 (7.60-11
Urea (mg/dL) 26.0 (24.0-28
Serum glutamic pyruvic transaminase (IU/L) 5.00 (2.00-10
Serum glutamic oxaloacetic transaminase (IU/L) 13.5 (2.00-18
The p-values are calculated using the Mann–Whitney U-test.the women presented recrudescent malaria during the
nine weeks of follow-up.
Five hundred sixty-four (564) post-dose plasma samples
of piperaquine were used in the pharmacokinetic analysis.
A total of 7 (1.2%) of these samples were measured to be
below the limit of quantification and omitted. A three-
compartmental disposition model resulted in a signifi-
cantly better model fit compared with a two-compartment
model (ΔOFV=−32.8). An additional peripheral com-
partment (four-compartment disposition model) did
not further improve the fit (ΔOFV=0). A transit-
compartment (n=3) absorption model was superior to
all other absorption models (ΔOFV≥−44.5). In the
final model the absorption rate constant (ka) and the
transit-compartment rate constant (ktr) were set equal
to increase the stability of the model. An additive
residual error model was adequate in describing
the residual random variability. BSV could be
estimated reliably on elimination clearance, one inter-
compartmental clearance parameter, and one periph-
eral volume parameter. The addition of BSV on the
bioavailability resulted in a significant improvement in
model fit (ΔOFV=−70.9). BOV had considerable
impact on both mean transit absorption time and bio-
availability (ΔOFV=−340). The final parameter esti-
mates and a schematic picture of the final structural
model is presented in Table 2 and Figure 1. Body
weight was incorporated with an allometric function on
all clearance and volume parameters (ΔOFV=−6.14).
Secondary parameters (i.e. total drug exposure, max-
imum concentration after first dose, time to maximum
concentration, elimination half-life and day 7 concentra-
tions) were analysed using the Mann–Whitney U-test tont women Pregnant women P-value
nge) Median (Range)
12 -
.2) 17.6 (13.6-21.7) 0.884
.9) 10.2 (7.83-12.5) 0.884
.0) 26.0 (18.0-33.0) 0.977
.0) 59.0 (50.0-72.0) 0.544
4) 166 (150–174) 0.908
32.0 (15.3–40.1) -
68700) 12900 (624–118000) 0.488
3 (1–6) 0.095
.0) 38.2 (36.6-39.9) 0.795
.5) 9.65 (8.00-12.0) 0.099
.0) 25.0 (24.0-28.0) 0.036
.0) 4.50 (2.00-9.00) 0.445
.0) 13.0 (3.00-21.0) 0.727
Table 2 Final parameter estimates describing the piperaquine population pharmacokinetics in women with
uncomplicated P. falciparum malaria
Population estimates [RSE %] 95% CI BSV/BOV† [RSE %] 95% CI
CL/F (L/h) 44.6 [9.90] 37.3-53.8 22.5 [31.5] 14.6-29.0
VC/F (L) 1820 [11.5] 1450-2240 - -
Q1/F (L/h) 47.7 [19.0] 32.4-69.2 - -
VP1/F (L) 15900 [12.3] 12600-20400 - -
Q2/F (L/h) 352 [11.1] 283-431 - -
VP2/F (L) 7520 [17.1] 5520-10500 - -
MTT (h) 1.70 [8.05] 1.45-2.00 60.7 [22.8] † 44.5-76.7
RUV 0.0973 [5.90] 0.0753-0.120 - -
No. of trans comp 3 fix - - -
F (%) 100 fix - 34.7 [59.2] 9.52-54.9
64.8 [15.2] † 52.8-76.0
Coefficient of variation (%CV) for between-subject variability (BSV) and (†) between occasion variability (BOV) were calculated as the [exp(estimated variance)-1]1/2.
Relative standard errors (RSE) and the 95% confidence intervals (CI) were based on 868 successful stratified bootstrap runs (out of 1000) and presented as
100×(standard deviation/mean value) and as 2.5 to 97.5 percentiles, respectively.
CL/F is the apparent elimination clearance. Vc/F is the apparent volume of distribution of the central compartment. Q1/F and Q2/F is the inter-compartment
clearance between the central and first and second peripheral compartment, respectively. VP1/F and VP2/F is the apparent volume of distribution of first and
second peripheral compartment, respectively. MTT is the mean transit time of the absorption model. RUV is the variance of the residual variability. No. of trans
comp is the number of transit compartments used in the absorption phase. F represents the relative bioavailability.
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women (Table 3). There was a significant difference in ter-
minal elimination half-life (p=0.0014), time to maximum
concentration (p=0.0177) and maximum concentration
(p=0.0205) [median (range) in pregnant vs. non-pregnant
women: 22.1 (19.1-25.8) vs. 25.7 (20.9-33.3) days, 3.07
(1.65-4.64) vs. 1.48 (0.887-4.18) hours and 185 (109–363)
vs. 102 (40.6-235) ng/mL, respectively]. However, no
significant differences were found in day 7 concentra-
tions (p=0.67), day 28 concentrations (p=0.84) or the
total drug exposure (p=0.80) between the pregnant and
non-pregnant women.Figure 1 The structural model for piperaquine pharmacokinetics. ktr is
of the central compartment, the first peripheral compartment and the seco
elimination clearance and Q1 and Q2 is the apparent inter-compartmentalThe MCMP analysis (5% significance level and 80%
power) indicated that 8+8 and 13+13 women are needed
to detect pregnancy as a covariate on elimination clear-
ance and bioavailability, respectively (Figure 2). A formal
stepwise covariate search was therefore not performed
since it might result in a biased covariate selection in
this small population sample.
Two full covariate models were constructed from the
final model to investigate the clinical relevance of preg-
nancy and EGA separately. Pregnancy had a relatively large
impact on mean transit absorption-time, volume of distri-
butions and inter-compartment clearances but nothe 1st order absorption rate. Vc, Vp1 and Vp2 are the apparent volume
nd peripheral compartment, respectively. CL is the apparent
clearances.
Table 3 Secondary parameters of piperaquine pharmacokinetics in pregnant and non-pregnant women with
uncomplicated P. falciparum malaria
Secondary parameters Total Non-pregnant women Pregnant women p-value
CMAX (ng/mL) 158 [40.6-363] 102 [40.6-235] 185 [109–363] 0.021
TMAX (hours) 2.62 [0.887-4.64] 1.48 [0.887-4.18] 3.07 [1.65-4.64] 0.018
Half-life (days) 23.4 [19.1-33.3] 25.7 [20.9-33.3] 22.1 [19.1-25.8] 0.001
Day 7 concentration (ng/mL) 58.3 [16.6-146] 55.4 [16.6-146] 60.7 [40.1-103] 0.671
Day 28 concentration (ng/mL) 15.9 [4.85-38.6] 15.4 [4.85-38.6] 16.1 [9.68-26.8] 0.840
AUC0->90 (ng*h/mL) 40600 [12400–100000] 38000 [12400–100000] 42700 [27100–68700] 0.799
AUC48h->90 (ng*h/mL) 36400 [10600–90300] 35300 [10600–90300] 37700 [23500–63200] 0.887
Secondary parameters are predicted using the final model and values are presented as median [range]. The p-values are calculated with a Mann–Whitney U-test.
CMAX is the predicted maximum concentration after the first dose and TMAX is the time to CMAX. Half-life is the estimated terminal elimination half-life. Day 7
and 28 concentrations are the model predicted plasma concentrations of piperaquine at day 7 and 28, respectively. AUC0->90 is the predicted area under the
concentration-time curve from time zero extrapolated to day 90. AUC48h->90 is the predicted area under the concentration-time curve from 48 hours extrapolated
to day 90.
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inclusion of EGA as a power function or a linear function
produced similar results. EGA was therefore implemen-
ted as a linear function for the full covariate approach
and resulted in similar results compared to pregnancy as
a categorical covariate (Figure 4A). Bootstrap results for
elimination clearance, stratified by trimester (i.e. non-
pregnant, second trimester at 20 weeks, and third trimes-
ter at 32 weeks) were also investigated and resulted in a
non-significant trend of increasing clearance with in-
creasing EGA (Figure 4B).
The final model resulted in good model diagnostic
performance and reliable parameter estimates (Figure 5
and Table 2). Calculated epsilon-shrinkage was low
(13.0%) which indicates that model diagnostics can
be assessed reliably. However, eta-shrinkage was rela-
tively high for certain parameters (CL/F=18.9%,Figure 2 Monte-Carlo Mapped Power (MCMP) curve for identifying pr
indentifying pregnancy as covariate on apparent elimination clearance and
the relative bioavailability. The dotted black line represents 80% power. The
pregnancy as a covariate given the used model and study sampling proceMTT=13.2-52.8%, F=12.4-46.6%) (Table 2) and empirical
Bayes estimates should therefore be interpreted with
caution (Table 3) [52]. The final model had good pre-
dictive performance (Figure 6) with 4.8% (95% CI.
1.4%-11%) of observed data below and 2.1% (95% CI.
1.4%-10%) of observed data above the simulated 90%
prediction interval (the three observations at day 90
were excluded because too few patients were followed
up to this time for reliable simulations).
Discussion
In this study, the pharmacokinetic properties of pipera-
quine have been investigated using nonlinear mixed-
effects modelling in pregnant and non-pregnant Sudanese
women treated with piperaquine-dihydroartemisinin for
uncomplicated P. falciparum malaria. Few studies have
been performed to evaluate the effect of pregnancy onegnancy as a covariate. Triangles represents the power curve for
circles is the power curve for identifying pregnancy as a covariate on
inserted numbers are the total number of subjects needed to identify
dure.
Figure 3 Box (25th to 75th percentile) and whisker
(1.5*interquartile range) plot of the full pregnancy-covariate
model for piperaquine. Pregnancy was included as a categorical
covariate and the solid black zero-line represents no covariate effect
and the dotted black lines represent a covariate effect of ±20%. MTT
is the mean transit time, Vc/F, Vp1/F and Vp2/F is the apparent
volume of the central compartment, the first peripheral
compartment and the second peripheral compartment respectively.
CL/F is the apparent elimination clearance and Q1/F and Q2/F is the
apparent inter-compartmental clearances.
A
Figure 4 Box (25th to 75th percentile) and whisker (1.5*interquartile ra
age implemented as a linear continuous covariate. Panel A displays the
zero-line represents no covariate effect. MTT is the mean transit time, Vc/F,
the first peripheral compartment ant the second peripheral compartment,
Q2/F is the apparent inter-compartmental clearances. Panel B displays the
the second trimester (week 20) and women in the third trimester (week 32
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is the first study conducted in an African population.
The treatment was well-tolerated and none of the partici-
pating women had recrudescent malaria infections.
Previous studies of piperaquine pharmacokinetics have
presented both two- and three-compartment disposition
models depending on the amount of data included in the
analysis [14,15,17,19,20,53]. A three-compartment dispos-
ition model described the piperaquine concentration-time
data adequately in this study. This supports the general
finding that a three-compartment disposition is more
appropriate than a two-compartment disposition when
modelling data from patients followed for a sufficient
period of time.
The absorption phase was best described with a tran-
sit compartment model with three transit compartments
including random effects on bioavailability (BSV and
BOV) and mean transit absorption time (BOV). The
transit-compartment model provides a more physio-
logical representation of the absorption process com-
pared to the absorption models used in previous studies
(i.e. first-order absorption and parallel first-order ab-
sorption with lag time) [15,17]. Recently published stud-
ies have also implemented the transit-compartment
model but with two- and five-transit compartments
which support the absorption model presented here
[19,20]. Small variations in the number of transit com-
partments are to be expected when modelling differentB
nge) plot of the full covariate model with estimated gestational
percent change per week of gestational age where the solid black
Vp1/F and Vp2/F is the apparent volume of the central compartment,
respectively. CL/F is the apparent elimination clearance and Q1/F and




Figure 5 Basic goodness-of-fit plots for the final piperaquine model. Observations plotted against population predicted concentrations (A)
and against individual predicted concentrations (B). Conditional weighted residuals plotted against population predicted concentrations (C) and
time (D). The solid line is the identity line and the broken line is the locally weighted least square regression line. The concentrations were
transformed into their logarithms (base 10). Conditional weighted residuals were fixed between 4 and −4, excluding one data point.
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dules and study size. The inclusion of BSV and BOV in
the absorption model improved the description of the
data in the absorption phase and accommodated the
large between-subject and between-occasion variability
in these data. The data in the absorption phase was
not rich enough to estimate separate absorption rates
for ka and ktr, and they were therefore set to be equal.
This is a common limitation and the same approach
has been used in previous studies [19,20]. Incorporating
BOV resulted in an increasing median bioavailability
(0.77, 1.19 and 1.40 at dose 1, 2 and 3, respectively)
and mean transit absorption time (1.55, 1.95 and 2.05 at
dose 1, 2 and 3, respectively) during the treatment regi-
men. Similar patterns have been identified in previously
studies on piperaquine [19]. This might be an effect of
disease recovery or differences in the food intake over
the course of the dose regimen. This cannot be veri-
fied since parasite densities were not counted at each
dose and food intake was not monitored in this study.
Pregnant women had a shorter terminal half-life com-
pared to non-pregnant women, which is in agreement
with the non-compartmental analysis [36], and highermaximum concentrations after the first dose. However,
there were no differences in total piperaquine exposure,
day 7 concentrations or day 28 concentrations, which
supports previously published findings in an Asian preg-
nant population [19].
The main aim of this study was to investigate the
pharmacokinetic differences between pregnant and
non-pregnant women, but the sample size was not large
enough to make a conventional covariate search. The
MCMP analysis resulted in a minimum of 13 patients
needed in each group in order to identify the previously
described covariate relationships with 80% power and a
significance level of 0.05 (Figure 2). However, this is
under the assumption of perfect sampling since the
MCMP analysis was based on simulated data using
protocol sampling times. In the present study, some
patients were not sampled for the complete follow-
period and some samples were randomly missing which
might increase the number of patients needed to iden-
tify the assumed covariate-relationships. Therefore the
final model did not include any covariates except
body weight, which has a strong biological prior
[47,48] and in addition gave a drop in OFV when
Figure 6 The visual predictive check of the final piperaquine model.. The circles represent the observations, the solid line represents the 5th,
50th and 95th percentile of the observed data. The shaded areas represent the simulated 95% confidence interval around the 5th, 50th and 95th
percentile. Concentrations were transformed to their logarithms (base 10). Predicted performance during the three first days is inserted in the top
right corner.
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fered from identifiability issues when incorporating the
pregnancy covariate simultaneously on clearance para-
meters, volume parameters and relative bioavailability.
The full covariate approach was therefore used to inves-
tigate the net effect of a potential covariate on all para-
meters except relative bioavailability. This approach
resulted in a model with reduced volume of distribution
and inter-compartment clearance in pregnant women
compared with non-pregnant women but no net-effect
on apparent clearance. This is in agreement with previ-
ously published results where pregnancy affected both
clearance and relative bioavailability but in different
directions [19]. These covariate relationships would also
explain the difference in terminal elimination half-life
and the lack of difference in total drug exposure.
The model presented in this study was built on data
from few patients and a single individual can thereforehave a considerable impact on the results. Piperaquine
population pharmacokinetic parameter estimates from
the final model are in agreement with previous reports
(Table 4). However, the elimination clearance presented
in this study for an African population is lower com-
pared to previous studies in non-pregnant and pregnant
patients. This might suggest an ethnicity related effect
on elimination clearance but this needs to be confirmed
in a larger population.
In conclusion, this study presents the population phar-
macokinetic properties of piperaquine in pregnant and
non-pregnant women with uncomplicated P. falciparum
malaria in Sudan. The terminal half-life was shorter in
pregnant compared to non-pregnant women, but the
total drug exposure was comparable between the two
groups. This supports previous findings that no dose
adjustments are needed on account of altered pipera-
quine pharmacokinetics in pregnancy.












Piperaquine pharmacokinetics in pregnant women
Pregnant Sudanese women with uncomplicated P. falciparum malaria 18-33 12 (0/12) 22.1 0.678 384 Pop PK This study
Pregnant Thai and Karen women with uncomplicated P. falciparum
malaria
18-43 24 (0/24) 17.5 1.28 529 Pop PK [19]
Piperaquine pharmacokinetics in non-pregnant populations
Non-pregnant Sudanese women with uncomplicated P. falciparum
malaria
16-43 12 (0/12) 25.7 0.739 446 Pop PK This study
Non-pregnant Thai and Karen women with uncomplicated
P. falciparum malaria
18-45 24 (0/24) 24.0 1.32 829 Pop PK [19]
Non-pregnant Thai and Karen males and females with uncomplicated
P. falciparum malaria
6-52 98 (59/39) 27.8 1.37 874 Pop PK [17]
Non-pregnant Cambodian males and females with uncomplicated
P. falciparum malaria
30±13† 38 (20/18) 22.6 0.900 574 Pop PK [14]
Healthy Vietnamese males 21-45 12 (12/0) 23.0 1.82 194 Pop PK [15]
Piperaquine pharmacokinetics in children
Children in Papua New Guinea with uncomplicated P. falciparum
and P. vivax malaria
7.1 ±1.5† 12 (8/4) 21.3 0.573* 385* Pop PK [54]
Children in Burkina Faso with uncomplicated P. falciparum malaria 2-10 236 (131/105) 23.2 0.417 214 Pop PK [20]
Children in Papua New Guinea with uncomplicated P. falciparum,
P. vivax and P. malariae malaria
6.9 ±1.4† 22 (17/5) 17.2 0.850 431 Pop PK [53]
Cambodian children with uncomplicated P. falciparum malaria 7±2† 47 (26/21) 13.5 1.85 614 Pop PK [14]
Influence of diet on piperaquine pharmacokinetics
Fasting non-pregnant Thai and Karen males and females with
uncomplicated P. falciparum malaria
18-55 15 (13/2) 17.5 1.19 700 NCA [18]
Fed non-pregnant Thai and Karen males and females with
uncomplicated P. falciparum malaria
19-41 15 (13/2) 21.4 1.01 769 NCA [18]
Healthy Caucasian males and non-pregnant women, low fat meal 19-42 8 (4/4) 20.3* 1.14* 716* NCA [16]
Healthy Caucasian males and non-pregnant women, high fat meal 19-42 8 (4/4) 20.9* 0.60* 365* NCA [16]
CL/F is the apparent elimination clearance, t1/2 is the elimination half-life, VD/F is the apparent volume of distribution, Pop PK represents a population
pharmacokinetic analysis and NCA represents a non-compartmental analysis. Age is given as a range or (†) as mean ± standard deviation. Other parameters are
given as median or as mean when indicated (*).
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